Cyclophosphamide (C)

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Neukio Biotherapeutics (Shanghai) Co., Ltd.

Conditions

AutoimmuneBreast CancerER+/HER2- Breast Cancer

Early Phase 1

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

RecruitingNCT07144462

Neukio Biotherapeutics (Shanghai) Co., Ltd.Autoimmune

Start: 2025-09-04End: 2027-01-14Target: 8Updated: 2025-08-27

Phase 2

Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

RecruitingNCT06964906

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityER+/HER2- Breast Cancer

Start: 2025-03-04End: 2030-12-31Target: 140Updated: 2025-05-11

Phase 3

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruitingNCT03725059

Merck Sharp & Dohme LLCBreast Cancer

Start: 2018-12-27End: 2031-01-24Target: 1240Updated: 2025-07-11

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

RecruitingNCT05159193

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBreast Cancer

Start: 2021-12-20End: 2028-01-31Target: 372Updated: 2024-02-02

Related Papers

Abstract P1-11-20: Chemotherapy use in patients with early-stage high-risk ER+/HER2- breast cancer in the United States (US) community setting: A retrospective observational cohort study

Clinical Cancer Research2025-06-13

Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trial.

2025-01-2158 citations

Checkpoint inhibition for early-stage hormone receptor-positive breast cancer.

2024-06-245 citations

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

Cancer Research2024-05-0216 citations

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer.

2022-12-2715 citations

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

Journal of Clinical Oncology2019-05-2025 citations